CY1114307T1 - COMPOSITIONS CONTAINING AQUORIN AND METHODS USED - Google Patents

COMPOSITIONS CONTAINING AQUORIN AND METHODS USED

Info

Publication number
CY1114307T1
CY1114307T1 CY20131100486T CY131100486T CY1114307T1 CY 1114307 T1 CY1114307 T1 CY 1114307T1 CY 20131100486 T CY20131100486 T CY 20131100486T CY 131100486 T CY131100486 T CY 131100486T CY 1114307 T1 CY1114307 T1 CY 1114307T1
Authority
CY
Cyprus
Prior art keywords
aquorin
compositions containing
methods used
methods
preventing
Prior art date
Application number
CY20131100486T
Other languages
Greek (el)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience, Llc filed Critical Quincy Bioscience, Llc
Publication of CY1114307T1 publication Critical patent/CY1114307T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)

Abstract

Με την παρούσα εφεύρεση παρέχονται συνθέσεις που περιέχουν αικουορίνη και μέθοδοι για την χρήση τους στην πρόληψη ή και την ελάφρυνση συμπτωμάτων και διαταραχών που σχετίζονται με ανισορροπία ασβεστίου.The present invention provides aquorin-containing compositions and methods for their use in preventing and / or alleviating symptoms and disorders associated with calcium imbalance.

CY20131100486T 2004-06-21 2013-06-14 COMPOSITIONS CONTAINING AQUORIN AND METHODS USED CY1114307T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
EP05766584.6A EP1768691B1 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
CY1114307T1 true CY1114307T1 (en) 2016-08-31

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100486T CY1114307T1 (en) 2004-06-21 2013-06-14 COMPOSITIONS CONTAINING AQUORIN AND METHODS USED

Country Status (21)

Country Link
US (3) US20060229243A1 (en)
EP (2) EP1768691B1 (en)
JP (1) JP4971150B2 (en)
KR (1) KR101213555B1 (en)
CN (1) CN1997383B (en)
AU (1) AU2005265266B2 (en)
BR (1) BRPI0512392B1 (en)
CA (1) CA2571542C (en)
CY (1) CY1114307T1 (en)
DK (1) DK1768691T3 (en)
ES (1) ES2422173T3 (en)
HK (1) HK1109576A1 (en)
IL (1) IL180195A (en)
MX (1) MXPA06015037A (en)
NZ (1) NZ552274A (en)
PL (1) PL1768691T3 (en)
PT (1) PT1768691E (en)
SG (1) SG153848A1 (en)
SI (1) SI1768691T1 (en)
WO (1) WO2006010004A2 (en)
ZA (1) ZA200610688B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
MX2010009753A (en) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Apoaequorin-containing compositions and methods of using same.
JP2010143860A (en) * 2008-12-19 2010-07-01 Chisso Corp Protein stabilizer
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
US9316588B2 (en) * 2010-12-24 2016-04-19 Otsuka Pharmaceutical Co., Ltd. Bioassay method for detecting physiologically active substance
MX350259B (en) * 2011-11-15 2017-08-31 Quincy Bioscience Llc Apoaequorin for reducing neuronal injury due to ischemia.
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (en) * 2000-03-01 2001-09-04 Masashi Sugimoto Bioluminescent method and luminescent article
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
AU2001268328A1 (en) * 2000-06-12 2001-12-24 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Also Published As

Publication number Publication date
EP2545934B1 (en) 2014-12-10
BRPI0512392B1 (en) 2022-12-13
ZA200610688B (en) 2007-12-27
EP2545934A1 (en) 2013-01-16
PT1768691E (en) 2013-06-20
DK1768691T3 (en) 2013-07-01
CN1997383A (en) 2007-07-11
JP4971150B2 (en) 2012-07-11
IL180195A (en) 2014-03-31
WO2006010004A2 (en) 2006-01-26
ES2422173T3 (en) 2013-09-09
AU2005265266A1 (en) 2006-01-26
CA2571542A1 (en) 2006-01-26
NZ552274A (en) 2010-06-25
SI1768691T1 (en) 2013-07-31
WO2006010004A3 (en) 2007-03-08
EP1768691A2 (en) 2007-04-04
PL1768691T3 (en) 2013-09-30
US7671015B2 (en) 2010-03-02
CA2571542C (en) 2014-08-19
US20100152117A1 (en) 2010-06-17
CN1997383B (en) 2011-01-05
AU2005265266B2 (en) 2011-05-12
SG153848A1 (en) 2009-07-29
HK1109576A1 (en) 2008-06-13
EP1768691A4 (en) 2010-08-04
KR101213555B1 (en) 2012-12-18
JP2008503581A (en) 2008-02-07
MXPA06015037A (en) 2007-07-11
KR20070070154A (en) 2007-07-03
US20080287350A1 (en) 2008-11-20
IL180195A0 (en) 2007-06-03
EP1768691B1 (en) 2013-05-22
US20060229243A1 (en) 2006-10-12
BRPI0512392A (en) 2008-03-11

Similar Documents

Publication Publication Date Title
CY1114307T1 (en) COMPOSITIONS CONTAINING AQUORIN AND METHODS USED
DE602005021694D1 (en) COMBINATION THERAPIES AGAINST MULTIPLE FABRIC LIKE RECEPTORS AND THEIR USE
CY1117476T1 (en) SUPPLEMENTARY COMPETITORS AND THEIR USES
ATE554114T1 (en) COPOLYMER WITH ZWITTERIONIC UNITS AND OTHER UNITS, COMPRISING COPOLYMER COMPOSITION AND USE
CY1110225T1 (en) CIRCULAR PROJECTS OF PROTEIN Tyrosine kinase
CY1116169T1 (en) COMPOSITIONS AND METHODS FOR USE OF PENNY PATTERNS AND ANALOGES
CY1116779T1 (en) AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICAL SUBSTANCES
CR9428A (en) METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
CY1110026T1 (en) Piperazine benzisoxazole compounds and methods of use thereof
ECSP077401A (en) MEDICATIONS CONTAINING CARBON COMPOUNDS AND THEIR USE
CY1110965T1 (en) ADDITIONAL HYPERPYROCYCLIC COMPOUNDS AND THEIR USE AS GLUTAMIC METHOD
NO20083397L (en) Anti-EphB4 antibodies and methods for their use
ECSP088543A (en) ANTI-OX40L ANTIBODIES AND METHODS THAT USE THEM
CR8766A (en) PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES
MX2009013199A (en) Anti-notch1 nrr antibodies and methods using same.
CY1112487T1 (en) REMOVAL-ACTIVE SLEEPING Hypnotic Factors for Anesthesia and Suppression
CY1109916T1 (en) Benzimidazolo-thiophene compounds as PLK inhibitors
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
ATE458740T1 (en) 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
CY1115384T1 (en) ANTI-INFLAMMATIVE COMPOSITION
CY1114366T1 (en) COMPOSITIONS CONTAINING DIAGNOSTIC AND METHODS OF USE
CY1114497T1 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF INTEGRITY
CY1111762T1 (en) OUTDOOR OUTDOOR OLANZAPIN
SE0301650D0 (en) Novel compounds